Drug-Pricing Measures On The Edge Left Out Of Senate Health Package

By Rachel Cohrs / June 19, 2019 at 3:51 PM
Senate health committee Chair Lamar Alexander (R-TN) and ranking Democrat Patty Murray (WA) ultimately decided not to include drug-pricing provisions that would tie patient coinsurance to net prices instead of list prices and require drug makers to justify price hikes in the committee’s final package on lowering health care costs. The committee added four FDA-related measures relating to generic drug label changes, conditions of use for different indications of biosimilars, criteria to obtain orphan drug designation exclusivity and safety labeling...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.